3Knoderer CA, Knoderer HM, Turrentine M, et al. Lepirudin anticoagulation for heparin induced throm bocytopenia afte: cardiac surgery in a pediatric patient [J]. Pharmacotherapy, 2006,26 ( 5 ) : 709 - 712.
4Keeling D ,Davidson S,W arson H, et al. The managem ent of heparin - induced thrombocytopenia[J]. Br J Haematol, 2006,135 (2) :269.
5Evans HC,Perry CM,Faulds D. Ximelagatran'Melagatran:Are view of its use in lhe prevention of venous thromboem holism in orthopaedic surgery[J]. Drugs,2004,64(6) :649 - 678.
6Bergurn PW, Cruikshank A, Maki SL, et al. Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor Ⅶ atissue factor complex by recombinant nematode anticoagulant protein c2[J]. J Biol Chem, 2001,276 (13) : 10063 - 10071.
7Banerjee Y. Mizuguchi J. Lwanaga S, eZ al. Hernextin AB Corn plex, a unique anticoagulant protein complex from Hemachatus haemachatus (African Ringhals Cobra) venom that inhibits clot initiation and factor Ⅶ a activity [J].J Biol Chem, 2005,280 ( 52 ) :42601-42611.
8Lassen MR, Bauer KA, Eriksson B1, et al. Postoperative fondapa rinux versus preoperative enoxaparin forprevention of venous thromboembolism in elective hjpreplacernentsurgery: A randomized double-blind comparison[J]. Lancet, 2002, 359(9319): 1715 - 1220.
10J Nakai T, Lesh MD,Gerstenfeld EP,et al. Pel - Cutaneous left Atrial appendage Occlusion (PLAATO) for preventing cardioem hollsm first experimentin canine model [J]. Circulation, 2002,105 (18) :2217 - 2222.
二级参考文献20
1[1]Conway DS,Pearce LA,Chin BS,Hart RG,Lip GY.Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation:relationnship to stroke risk factors[J].Circulation,2002,106(15):1962-7.
2[2]Conway DS,Heeringa J,Van Der Kuip DA,Chin BS,Hofman A,Witteman JC,Lip Gy.Atrial fibrllation and the prothrombotic state in the elderly:the Rotterdamstudy[J].Stroke,2003,34(2):413-7.
3[3]Li-Saw-Hee FL,Blann AD,Lip GY.A cross-sectinal and diurnal study of thrombogenesis among patients with chronic atrial fibrillation[J].Am Coll Cardiol,2000,35(7):1926-31.
4[4]Goldsmith IR,Foo LS,Blann AD,Lip GY.Increased platelet activation and endothelial dysfunction in patients with atrial fibrillation immediately following percutaneous balloon mitral valvuloplasty[J].Clin Cardiol,2000,23(8):587-90.
5[5]Li-Saw-Hee FL,Blann AD,Edmunds E,Gibbs CR,Lip GY.Effect of acute exercise on the raised plasma fibrinogen,soluble P-selectin and von Willebrand factor levels in chronic atrial fibrillation[J].Clin Cardiol,2001,24(5):409-14.
6[6]Li-Saw-Hee Fl,Blann AD,Gurney D,Lip GY.Plasma von Willebrand factor,fibrinogen and soluble P-selectin levels in paroxysmal,persistent and permanent atrial fibrillation.Effects of cardioversion and return of left atrial function[J].Eur Heart J,2001,22(18):1741-7.
7[7]Mondillo S,Sabatini L,Agricola E,Ammaturo T,Guerrini F,Barbati R,Pastore M,Fineschi D,Nami R.Correlation between left atrial size,prothrombotic state and markers of endothelial dysfunction in patients with long chronic nonrheumatic atrial fibrillation[J].Int J Cardiol,2000.
8[8]Kozuka K,Kohriyama T,Nomura E,Ikeda J,Kajikawa H,Nakamura S.Endothelial markers and adhesion molecules in acute ischemic stroke-sequential change and differences in stroke subtype[J].Atherosclerosis,2002,161(1):161-8.
9[9]Blann AD,Lip GY.Beevers DG,McCollum CN.Soluble P-selectin in atherosclerosis:a comparison with endothelial cell and platelet markers[J].Thromb Haemost,1997,77(6):1077-80.
10[10]Go AS,Hylek EM,Phillips KA,Borowsky LH,Henault LE,Chang Y,Selectinby JV,Singer DE.Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation:the Anticoagulation and Risk Factors in Atrialfibrillation(ATRIA)study[J].Circulation,2000,102(1):11-3.
